Vanguard Personalized Indexing Management LLC Sells 13,032 Shares of Bristol-Myers Squibb (NYSE:BMY)

Vanguard Personalized Indexing Management LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 10.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,949 shares of the biopharmaceutical company’s stock after selling 13,032 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Bristol-Myers Squibb were worth $4,715,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. E Fund Management Co. Ltd. raised its position in Bristol-Myers Squibb by 13.2% in the 2nd quarter. E Fund Management Co. Ltd. now owns 7,190 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 840 shares during the last quarter. Wealth Alliance increased its stake in shares of Bristol-Myers Squibb by 13.8% in the second quarter. Wealth Alliance now owns 44,503 shares of the biopharmaceutical company’s stock valued at $1,848,000 after buying an additional 5,390 shares in the last quarter. Axxcess Wealth Management LLC raised its holdings in shares of Bristol-Myers Squibb by 4.6% in the second quarter. Axxcess Wealth Management LLC now owns 76,958 shares of the biopharmaceutical company’s stock valued at $3,196,000 after buying an additional 3,404 shares during the last quarter. Alpha Family Trust acquired a new position in Bristol-Myers Squibb during the 2nd quarter worth about $387,000. Finally, Peregrine Asset Advisers Inc. grew its holdings in Bristol-Myers Squibb by 46.7% during the 2nd quarter. Peregrine Asset Advisers Inc. now owns 22,964 shares of the biopharmaceutical company’s stock worth $954,000 after acquiring an additional 7,310 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the subject of a number of research analyst reports. Jefferies Financial Group boosted their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research note on Wednesday, August 28th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. TD Cowen increased their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a research report on Monday, August 12th. Barclays boosted their target price on Bristol-Myers Squibb from $41.00 to $42.00 and gave the stock an “underweight” rating in a research report on Thursday, August 22nd. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $55.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $49.74 on Thursday. The firm’s 50 day simple moving average is $47.34 and its 200 day simple moving average is $46.48. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $59.46. The company has a market capitalization of $100.83 billion, a price-to-earnings ratio of -16.05, a P/E/G ratio of 12.59 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The company had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same period last year, the business posted $1.75 earnings per share. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.77 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.83%. Bristol-Myers Squibb’s payout ratio is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.